| Title: |
Ceftolozane/tazobactam in action: Prescribing patterns, effectiveness, and healthcare utilisation across seven countries |
| Authors: |
Emre Yucel; Alex Soriano; David L. Paterson; Florian Thalhalmmer; Stefan Kluge; Pierluigi Viale; Mike Allen; Brune Akrich; Jessica Levy; Huina Yang; Sunny Kaul |
| Source: |
Journal of Global Antimicrobial Resistance, Vol 46, Iss , Pp 14-21 (2026) |
| Publisher Information: |
Elsevier, 2026. |
| Publication Year: |
2026 |
| Collection: |
LCC:Microbiology |
| Subject Terms: |
Ceftolozane; Tazobactam; Countries; Clinical success; Mortality; Prescribing patterns; Microbiology; QR1-502 |
| Description: |
Objectives: Infections by antimicrobial-resistant, Gram-negative bacteria present significant global challenge, resulting in difficult treatment scenarios and poor clinical outcomes. Although ceftolozane/tazobactam (C/T) has been approved for the treatment of hospital-acquired HABP/VABP, cUTI, and cIAI, data on real-world use remains limited. This study presents real-world use of C/T across various countries. Methods: The Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam: Real-world Analysis (SPECTRA) was a retrospective, observational study involving 617 adult inpatients across seven countries who were treated with C/T for at least 48 hours between 2016 and 2020. The primary objective was to describe real-world utilisation of C/T, focusing on sociodemographic and clinical characteristics, treatment patterns, clinical outcomes, and resource utilisation. Results: 617 patients from seven countries were included. Prevalence of at least one comorbidity ranged from 55.9% (Mexico) to 91.7% (Austria), with mean number of comorbidities from 1.0 (Mexico) to 2.7 (UK). Culture results from 72.7% patients identified MDR Pseudomonas aeruginosa, ranging from 55.9% (Italy) to 80.6% (Spain). Median hospital length of stay ranged from 23 (Mexico) to 53.5 (Austria) days. Clinical success rate for treating the index infection with C/T was 64.8%, with 51.1% of cases treated within the ICU. Conclusions: This multi-national, retrospective, observational study demonstrates the real-world use and healthcare resource utilisation (HCRU) of C/T in patients with Gram-negative infections across seven countries. These findings provide valuable insights into prescribing patterns and resource implications of C/T treatment, underscoring the importance of real-world data to inform clinical practice and optimise antimicrobial therapy in diverse healthcare settings. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2213-7165 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S2213716525002322; https://doaj.org/toc/2213-7165 |
| DOI: |
10.1016/j.jgar.2025.10.013 |
| Access URL: |
https://doaj.org/article/0f01acbfd70e4ab1bec74bc556990be7 |
| Accession Number: |
edsdoj.0f01acbfd70e4ab1bec74bc556990be7 |
| Database: |
Directory of Open Access Journals |